Legacy Wealth Asset Management LLC Lowers Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Legacy Wealth Asset Management LLC reduced its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,744 shares of the medical equipment provider’s stock after selling 231 shares during the quarter. Intuitive Surgical comprises approximately 0.8% of Legacy Wealth Asset Management LLC’s portfolio, making the stock its 17th biggest holding. Legacy Wealth Asset Management LLC’s holdings in Intuitive Surgical were worth $2,822,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of ISRG. International Assets Investment Management LLC raised its stake in shares of Intuitive Surgical by 49,383.6% during the third quarter. International Assets Investment Management LLC now owns 1,090,619 shares of the medical equipment provider’s stock worth $535,788,000 after acquiring an additional 1,088,415 shares in the last quarter. Capital Research Global Investors purchased a new position in shares of Intuitive Surgical during the first quarter worth approximately $374,390,000. Vanguard Group Inc. raised its stake in shares of Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after acquiring an additional 302,382 shares in the last quarter. Finally, Strategic Financial Concepts LLC raised its stake in shares of Intuitive Surgical by 40,221.4% during the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after acquiring an additional 265,461 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Truist Financial lifted their price target on shares of Intuitive Surgical from $520.00 to $570.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Barclays raised their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. Mizuho raised their target price on shares of Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Morgan Stanley raised their target price on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Finally, Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their target price for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $511.27 on Friday. The firm has a market capitalization of $182.10 billion, a P/E ratio of 82.20, a PEG ratio of 5.11 and a beta of 1.39. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $523.34. The company’s 50-day simple moving average is $487.34 and its 200 day simple moving average is $441.45.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of Intuitive Surgical stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Mark Brosius sold 2,128 shares of the stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total value of $1,095,920.00. Following the completion of the sale, the senior vice president now directly owns 273 shares in the company, valued at approximately $140,595. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 52,192 shares of company stock valued at $25,398,571 in the last ninety days. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.